

Catalog Number: CM00141

产品信息

Catalog Number:
CM00141

CAS号:
53994-73-3

分子式:
C₁₅H₁₄ClN₃O₄S

主要靶点:
Antibacterial

主要通路:
Anti-infection


分子量:
367.8074

MDL NO:
MFCD00151471

Pubchem ID:
51039

溶解度:

DMSO	insoluble
Water	insoluble
Ethanol	insoluble



描述

Cefaclor is a well-absorbed oral cephalosporin antibiotic. Peak concentrations in serum are attained within 30 - 60 minutes. Cefaclor is not metabolized to a significant degree, but it degrades chemically in the body with an approximate half-life of 2 hours^[3]. Cefaclor is active against a wide range of commonly encountered bacterial pathogens, acting by inhibiting cell wall synthesis. Its in vitro activity compares favourably with other beta-lactam antibiotics. Cefaclor has been widely used in infections of the respiratory tract (including otitis media), urinary tract and soft tissues^[4]. Multiple clinical trials have shown that extended-release cefaclor in 375-mg and 500-mg doses BID demonstrates tolerability and efficacy comparable to those of immediate-release cefaclor 250 mg TID^[5]. Moreover, only collagen scaffolds loaded with 100 μg/ml Cefaclor exhibited adequate antibacterial properties against both 10⁶ and 10⁸ colony-forming units per ml of both *Escherichia coli* and *Staphylococcus epidermidis*^[6]. Patients with cefaclor anaphylaxis exhibit high serum IgE levels. A cut-off value of 0.11 kU/L of sIgE (serum-specific IgE) to cefaclor is proper for identifying patients with cefaclor allergy, and 0.44 kU/L may be useful to detect anaphylaxis^[7].

储存

储存条件:

粉末	-20°C	3年
液体	-80°C	1年

运输条件:

Shipped in cold pack

参考文献

- 1 King BA, Geelhoed GC. Adverse skin and joint reactions associated with oral antibiotics in children: the role of cefaclor in serum sickness-like reactions. *J Paediatr Child Health.* 2003 Dec;39(9):677-81.
- 2 Ito S, Blajchman A, et al. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. *Am J Obstet Gynecol.* 1993 May;168(5):1393-9.
- 3 Sourgens H, Derendorf H, Schifferer H. Pharmacokinetic profile of cefaclor. *Int J Clin Pharmacol Ther.* 1997;35(9):374 - 380
- 4 Brumfitt W, Hamilton-Miller JM. Cefaclor into the millennium. *J Chemother.* 1999;11(3):163 - 178
- 5 Meyers BR. Cefaclor revisited. *Clin Ther.* 2000;22(2):154 - 166
- 6 Tsekoura EK, Helling AL, Wall JG, Bayon Y, Zeugolis DI. Battling bacterial infection with hexamethylene diisocyanate cross-linked and Cefaclor-loaded collagen scaffolds. *Biomed Mater.* 2017;12(3):035013. Published 2017 Jun 19
- 7 Nam YH, Lee SH, Rhyou HI, et al. Proper Cut-off Levels of Serum Specific IgE to Cefaclor for Patients with Cefaclor Allergy. *Yonsei Med J.* 2018;59(8):968 - 974